The Beauty Health Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
$SKIN
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices)
(Zip Code)
(800 ) 603-4996
(Registrant’s telephone number, including area code)
2165 Spring Street
Long Beach, CA 90806
Long Beach, CA 90806
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
The | ||||||||||||||
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On March 3, 2026, The Beauty Health Company (the “Company”) gave notice to its stockholders of record as of February 20, 2026, that on February 9, 2026, the parties to the consolidated stockholder derivative action pending in the Delaware Court of Chancery, captioned Elstein v. Saunders et al. (In re The Beauty Health Co. Consolidated S’holder Litig.), C.A. No. 2024-0114-LWW (Del. Ch.) (the “Consolidated Derivative Action”), entered into a Stipulation of Settlement (the “Stipulation”), which is subject to court approval, to resolve all claims in the Consolidated Derivative Action described in Note 6 of the Condensed Consolidated Financial Statements of the Company for the period ended September 30, 2025 included in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025.
On February 20, 2026, the Delaware Court of Chancery entered a Scheduling Order with Respect to Notice and Settlement Hearing (the “Scheduling Order”), which requires that the Company file a copy of the Notice of Pendency and Proposed Settlement of Derivative Action (the “Notice”) as an exhibit to a Current Report on Form 8-K. A copy of the Notice is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
The description and summary of the pending settlement is qualified in its entirety by reference to the Stipulation and all exhibits thereto, including the Notice, which can be found on the Stock Information – Legal Notices page of the Company’s website at: https://www.beautyhealth.com/legal-notices.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: March 6, 2026 | The Beauty Health Company | |||||||
| By: | /s/ Michael Monahan | |||||||
| Name: | Michael Monahan | |||||||
| Title: | Chief Financial Officer | |||||||